New Drug Landscape Dominated by High-cost Medicines

February 19, 2019

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2017 edition of Meds Entry Watch, an annual publication that provides the latest information on new medicines entering Canadian and international markets.

Patented Medicine Prices Review Board issues a Notice of Hearing for allegations of excessive pricing of Procysbi

January 16, 2019

The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name “Procysbi” by the patentee Horizon Therapeutics Canada.

Canadian per capita use and spending on drugs for chronic retinal diseases among the highest in the OECD

December 12, 2018

Spending on drug class grew by 16.7% in 2017 and stands at just under $700 million

Patented Medicine Prices Review Board seeks applicants for Vice-Chairperson and Board member positions

December 5, 2018

Governor in Council selection processes underway

Public Drug Plan Expenditures Continue to Rise in 2016-17

September 11, 2018

Increased spending on high cost drugs and reduced savings from generics responsible for 6.3% average growth over 2 years.

PAGE 1 - 2 - 3 - 4 - 5  NEXT 25  LAST 5 
Date modified: